09/17/23 12:00 PMNasdaq : ENTA conferenceslow floatEnanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza ConferenceEnanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus, will be presented at the 9th European Scientific Working Group on...RHEA-AIneutral
09/07/23 7:00 AMNasdaq : ENTA conferenceslow floatEnanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus, will be presented at IDWeek 2023 being held October 11- 15, 2023 at the...RHEA-AIneutral
08/31/23 7:00 AMNasdaq : ENTA conferenceslow floatEnanta Pharmaceuticals to Participate in Investor Conferences in SeptemberEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that members of management will participate in four investor conferences being webcast in September and provide a business update:. Wells Fargo Securities Healthcare Conference: Fireside Chat at...RHEA-AIneutral
08/07/23 4:01 PMNasdaq : ENTA earningslow floatEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ETEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal third quarter ended June 30, 2023.. Total revenue for the three months ended June 30, 2023 was $18.9 million and consisted of royalty revenue from worldwide net sales of...RHEA-AIneutral
07/31/23 7:00 AMNasdaq : ENTA conferencesearningslow floatEnanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2023 after the U.S. market closes on August 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to...RHEA-AIneutral
06/20/23 7:00 AMNasdaq : ENTA clinical triallow floatEnanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial VirusEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics of orally administered single ascending doses and multiple ascending doses of EDP-323 in healthy...RHEA-AIneutral
06/07/23 7:00 AMNasdaq : ENTA low floatEnanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’ s out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver International Liver Congress 2023 being...RHEA-AIneutral
05/31/23 7:00 AMNasdaq : ENTA conferenceslow floatEnanta Pharmaceuticals to Participate at Jefferies Global Healthcare ConferenceEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Jefferies Global Healthcare Conference on June 7, 2023 at 12:30 p.m. ET in New York, NY.RHEA-AIneutral
05/09/23 7:00 AMNasdaq : ENTA conferenceslow floatEnanta Pharmaceuticals to Participate in Two Investor Conferences in MayEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in May:. JMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on May...RHEA-AIneutral
05/08/23 4:01 PMNasdaq : ENTA clinical trialcovid-19low floatEnanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced topline data from SPRINT, a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta’ s oral, 3 CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19...RHEA-AIneutral